Contact us

    MrMrsMsDr



    Collection and Use of Personal Information. *

    [Peer-Reviewed Publications] Prostate International – Artificial intelligence–driven digital pathology in urological cancers: current trends and future directions

    p2287-8882 e2287-903X/© 2025 The Asian Pacific Prostate Society. Published by Elsevier B.V., 2025
    doi.org/10.1016/j.prnil.2025.02.002
    Published: February 2025

    Authors: Inyoung Paik, Geongyu Lee, Joonho Lee, Tae-Yeong Kwak, Hong Koo Ha

    Abstract

    Artificial intelligence (AI) in digital pathology has gained attention owing to its potential in urological cancer diagnosis and management. This review highlights AI’s applications and challenges in three major urological cancers. Prostate cancer studies have demonstrated reliable diagnostic performance and promising prognosis prediction. Renal cancer study shows potential but faces challenges in generalizability and prognosis. Bladder cancer studies are limited by the lack of large-scale datasets. Despite of these active studies, challenges remain regarding data availability, prognosis, and generalizability. Future efforts should emphasize multimodal approaches and multi-institutional collaboration with larger datasets to fully realize the potential of AI in urological cancers.

    Keywords: Artificial intelligence, Deep learning, Digital pathology, Urological cancers

    Deep Bio and PathAI Collaborate to Drive AI-Powered Innovations in Digital Pathology

    SEOUL, SOUTH KOREA, November 19, 2024 /EINPresswire.com/ — Deep Bio, a leader in artificial intelligence for digital pathology, announced a collaboration to integrate its prostate cancer analysis solution, DeepDx Prostate, with PathAI’s AISight®1 Image Management System (IMS). This collaboration combines Deep Bio’s clinically validated AI technology with PathAI’s advanced digital pathology platform, expanding access to powerful diagnostic tools for prostate cancer.

    DeepDx Prostate, which is CE-marked and clinically validated, provides AI-supported diagnostics for prostate cancer by analyzing digitized slide images of Hematoxylin & Eosin (H&E) stained prostate specimens. The software classifies each lesion by histological type or risk grade, measures lesion size, and generates metrics crucial for cancer diagnosis, prognosis, and treatment planning, including lesion type proportions and overall tissue lesion ratios.

    PathAI, the developer of the AISight IMS platform, is a pioneering provider of AI-powered research tools and services for pathology, working with leading life sciences companies, laboratories, and researchers to advance precision medicine. AISight is a complete solution for primary diagnosis, centralizing case and image management in a cloud-native, intelligent platform. It provides pathologists with an intuitive way to view, interpret, share, and manage whole slide images, enhancing both confidence and efficiency in diagnostic workflows. Ideal for clinical settings of all sizes—from individual labs to large hospital networks—AISight is utilized by premier laboratories and research centers globally to streamline digital pathology workflows and AI applications, serving as a central hub equipped with top-tier AI tools for multiple histopathology applications.

    “We are thrilled to integrate DeepDx Prostate with PathAI’s AISight IMS platform,” said Deep Bio CEO Sun Woo Kim. “This collaboration allows broader access to our AI-driven diagnostic tools, and we aim to transform prostate cancer diagnostics by empowering clinicians with advanced tools to guide treatment decisions.”

    “We are excited to welcome Deep Bio’s DeepDx Prostate algorithm into the AISight platform,” said Andy Beck, CEO of PathAI. “This collaboration exemplifies our commitment to equipping pathologists with cutting-edge tools that enhance precision and increase workflow efficiency. By expanding the reach of advanced AI solutions, we continue to make meaningful strides in improving patient outcomes and transforming digital pathology on a global scale.”

    Leveraging PathAI’s rapidly growing install base of AISight users, through this integration, DeepDx Prostate will reach a wider range of clinicians and patients across North America and Europe, providing access to leading-edge diagnostic tools for prostate cancer. This collaboration marks a pivotal step toward Deep Bio’s vision of advancing AI-powered cancer diagnostics on a global scale.

    About Deep Bio

    Deep Bio is a pioneer in AI-powered pathology, transforming cancer diagnostics with innovative solutions that support pathologists in delivering precise and efficient care. Its flagship product, DeepDx Prostate, is a CE-IVD-marked diagnostic aid extensively vetted through studies of over 700,000 U.S. biopsy specimens. Offering tools for cancer detection, Gleason scoring, and gland-level tumor analysis, DeepDx Prostate enhances diagnostic accuracy while streamlining pathology workflows. Deep Bio’s commitment to advancing digital pathology is driven by collaboration and a dedication to improving patient outcomes

    Note: AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK

    Deep Bio’s AI Model for Prostate Cancer Assessment Validated by Researchers

    Deep Bio Inc., a leader in AI-driven digital pathology solutions, announced the publication of an external validation study for its DeepDx Prostate AI algorithm, conducted by Stanford Medicine.
    The study, titled “External Validation of an Artificial Intelligence Model for Gleason Grading of Prostate Cancer on Prostatectomy Specimens,” was published in the British Journal of Urology International.

    SEOUL, SOUTH KOREA, August 6, 2024

    The study evaluated the performance of DeepDx Prostate in detecting and grading prostate cancer on whole-mount radical prostatectomy (RP) specimens. The DeepDx Prostate algorithm, which had been originally trained and validated on prostate core needle biopsy (CNB) images from two hospitals in South Korea, was tested to determine its generalizability to different patient populations and much larger prostatectomy specimens. Researchers aimed to assess the model’s performance on RP specimens from an institution it had never encountered before, without any fine-tuning. The validation study demonstrated the following key findings:

    1. High Accuracy: The algorithm achieved an impressive sensitivity of 0.997 and specificity of 0.88 in detecting cancer presence in radical prostatectomy specimens.
    2. Agreement with Pathologists: The AI showed strong agreement with expert uropathologists, with Cohen’s Kappa values of UWK 0.91 for cancer presence, QWK 0.89 for Gleason grade classification, and QWK 0.89 for risk group identification (benign, low [GG1], intermediate [GG 2-3], and high-risk [GG 4-5]).
    3. Generalizability: The algorithm demonstrated robust performance across different datasets and tissue types, highlighting its potential for widespread implementation across various healthcare settings.

    Sun Woo Kim, CEO of Deep Bio, commented, “Accurate grading of Gleason scores is key to optimizing treatment plans and predicting outcomes. The swift and precise results provided by DeepDx Prostate will be invaluable in clinical practice.”

    Bogdana Schmidt MD, MPH, the lead author of this validation study and current assistant professor at the University of Utah, said, “The validation of DeepDx Prostate through this study underscores its generalizability and potential for widespread clinical implementation. This tool will aid in the timely and accurate grading of prostate cancer, which is crucial for developing effective treatment plans.”

    The study concludes that DeepDx Prostate algorithm is an accurate tool for identifying and grading prostate cancer on digital histopathology images of whole-mount RP specimens, demonstrating almost perfect concordance with expert GU pathologists and impressive performance in various clinically relevant tasks.

    Deep Bio Inc. is committed to advancing AI technology to enhance diagnostic accuracy and efficiency in pathology. When used for its intended tissue type—CNB samples—DeepDx Prostate demonstrates 99% sensitivity and 97% specificity.

    About Deep Bio

    Established in 2015, Deep Bio Inc. is a medical AI development company specializing in deep learning and cancer pathology diagnostics. The company develops in-vitro diagnostic medical device software (IVD SaMD) that enhances the accuracy of cancer diagnosis and prognosis, aiding in better treatment decision-making.

    Deep Bio’s prostate cancer diagnostic AI solution, which has obtained the European CE-IVD certification, analyzes high-resolution Whole Slide Images (WSI) to identify and segment cancerous lesions. The software classifies each lesion by histological type or risk grade, measures lesion size, and provides various metrics, such as the proportion of each lesion type and the overall tissue lesion ratio, essential for cancer diagnosis, prognosis, and treatment planning.

    The AI solution provides detailed analysis results and reports, improving patients’ and professionals’ accessibility to medical information. This innovation earned Deep Bio the CES Innovation Award in 2024.

    Dr. Fouad Kettani’s Experience Using DeepDx Prostate: A Testimonial

    We are thrilled to share the insights of Dr. Fouad Kettani, who recently tested our DeepDx Prostate solution. Dr. Kettani highlighted several positive aspects of our product, particularly emphasizing its ease of use and the depth of AI-generated results.
    He noted that DeepDx Prostate significantly reduces subjectivity and inter-observer variability, marking it as a valuable tool in prostate cancer diagnostics.

    Don’t miss his full testimonial to understand how DeepDx Prostate can enhance diagnostic accuracy and improve patient outcomes.

    Deep Bio Unveils Research Findings on Performance Evaluation of AI Algorithm for Breast Cancer Analysis

    Deep Bio utilizes deep learning-based algorithms to differentiate breast cancer lesions accurately, optimizing diagnostic accuracy

    SEOUL, SOUTH KOREA, May 21, 2024

    Deep Bio today announced the publication of a study evaluating the performance of its AI algorithm for breast cancer analysis to accurately differentiate between invasive ductal carcinoma (IDC) lesions from non-invasive ductal carcinoma in situ (DCIS) lesions in biopsies taken after breast cancer surgery.

    The research, conducted in collaboration with the Catholic University of Korea Bucheon St. Mary’s Hospital and Korea University Guro Hospital, has been published in a special issue of MDPI Bioengineering titled “Computational Pathology and Artificial Intelligence.”

    Breast cancer is the most prevalent cancer among women worldwide, accounting for 24.5% of all female cancers, with a mortality rate of 15.5%, the highest among women’s cancers. Pathologically, breast cancer is categorized into various types, with invasive ductal carcinoma (IDC) being the most common, constituting 70-80% of all cases. Accurate differentiation between IDC and ductal carcinoma in situ (DCIS) is critical for effective treatment planning. The “2022 Korean Breast Cancer White Paper” published by the Korean Breast Cancer Society, reported 24,933 IDC and 4,816 DCIS cases in South Korea in 2019, underscoring the need for precise diagnostic tools. Predicting the characteristics, size, and severity of lesions in invasive ductal carcinoma (IDC) and non-invasive ductal carcinoma (DCIS) accurately through this study indicates a significant advancement.

    Traditional pathology involves examining cancer cells’ growth patterns and histological characteristics using a microscope. However, mixed patterns of IDC and DCIS within the same lesion can complicate manual assessment and prognosis prediction. This is where AI-powered algorithms can revolutionize diagnostics.

    Specifically, Deep Bio’s Multi-resolution Selective Segmentation Model for Breast Cancer (MurSS) addresses these challenges by analyzing hematoxylin and eosin (H&E) stained breast cancer pathology slide images to segment breast cancer lesions automatically. This model enhances diagnostic accuracy by leveraging multi-resolution images and introduces a selective segmentation method to automatically exclude uncertain areas from learning, thereby increasing the stability and reliability of model results.

    MurSS achieved a pixel-level accuracy of 96.88% (95% confidence interval 95.67% to 97.61%) on breast cancer H&E slides, outperforming existing deep learning models.

    CTO Tae-Yeong Kwak of Deep Bio said, “Using the Multi-resolution Selective Segmentation Model (MurSS), we can more accurately measure cancer areas on whole slide image of breast tissues, aiding in the measurement of invasive cancer area by excluding in situ carcinomas,” he added. “I hope our AI algorithm for breast cancer enables pathologists to identify precise cancer lesions by improving predictions with automated cancer marker analysis.”

    Deep Bio continues to innovate with AI solutions for breast cancer analysis. DeepDx® Breast – Resection is a screening solution that automatically detects areas of interest in breast excision slide images, while DeepDx® Breast – SLNB (Sentinel Lymph Node Biopsy) has maintained its top performance since securing first place in the Camelyon17 Challenge in 2019, a global image analysis competition focused on breast cancer lymph node metastasis detection.

    About Deep Bio

    Deep Bio is an AI healthcare company dedicated to advancing the field of cancer pathology. Focusing on deep learning, the company develops cutting-edge In Vitro Diagnostic Software as Medical Devices (IVD SaMDs) to empower pathologists and medical professionals with state-of-the-art tools for more accurate cancer diagnosis and prognosis.

    For more information, visit the website: www.deepbio.co.kr.